Dermata Therapeutics stockholders approve reverse stock split and director elections at 2025 meeting

Dermata Therapeutics, Inc.

Stockholders elected Mary Fisher and Andrew Sandler as Class I directors for three-year terms.
Ratified Baker Tilly US, LLP as independent auditor for FY2025 with 3,229,829 votes for.
Approved issuance of shares underlying warrants from Jan 2025 SPA and March 2025 inducement letter (over 20% of outstanding).
Authorized reverse stock split at ratio between 1:2 and 1:30, with board to determine exact ratio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.